HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 5, 2009, Pages 1385-1389

  Roses, Robert E ^a   Paulson, E Carter ^a   Sharma, Anupama ^a   Schueller, Jeanne E ^a   Nisenbaum, Harvey ^a   Weinstein, Susan ^a   Fox, Kevin R ^a   Zhang, Paul J ^a   Czerniecki, Brian J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Surgery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; ASSOCIATION; BREAST CANCER; BREAST NECROSIS; CANCER GRADING; CANCER INVASION; CANCER SIZE; CLINICAL TRIAL; FEMALE; GENE OVEREXPRESSION; GROUPS BY AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; ONCOGENE NEU; PREDICTOR VARIABLE; PRIORITY JOURNAL; BIOPSY; BREAST; BREAST TUMOR; CARCINOMA IN SITU; CHI SQUARE DISTRIBUTION; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY;

BIOPSY; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 66549130199     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-1101     Document Type: Article

References (15)

1. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002;94:1546-1554 (Pubitemid 35277278)
2. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008;14:370-378
3. Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992;23:974-979
4. Czerniecki BJ, Koski GK, Koldovsky U, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007;67:1842-1852 (Pubitemid 46383411)
5. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212-9217 (Pubitemid 29374734)
6. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006;19:617-621
7. Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetkova E. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ . Cancer 2006;107:1760-1768 (Pubitemid 44582944)
8. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ . J Am Coll Surg 2005;200:516-526 (Pubitemid 40432319)
9. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008;10:R67.
10. Wolf-Yadlin A, Kumar N, Zhang Y, et al. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol 2006;2:54. (Pubitemid 46061069)
11. Wen XF, Yang G, Mao W, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006;25:6986-6996 (Pubitemid 44684839)
12. Subbaramaiah K, Howe LR, Port ER, et al. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 2006;66:5504-5511 (Pubitemid 43844979)
13. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Anticancer Res 2005;25:1719-1723 (Pubitemid 40896793)
14. Hoque A, Sneige N, Sahin AA, et al. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2002;11:587-590 (Pubitemid 34615167)
15. Layfield LJ, Lewis C. In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status. Anal Quant Cytol Histol 2007;29:239-243